Skip to content

Clinical trials

Phase 1/2 Graft vs Host Disease trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Graft vs Host Disease Phase: Phase 1/2 Clear all

87 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20011
20023
20032
20042
20052
20062
20074
20083
20098
20102
20115
20124
20132
20147
20153
20162
20174
20183
20194
20203
20212
20222
20231
20244
20253
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed37
Unknown status19
Terminated10
Active, not recruiting7
Recruiting5
Not yet recruiting4
Withdrawn3
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center7
Hadassah Medical Organization4
M.D. Anderson Cancer Center4
H. Lee Moffitt Cancer Center and Research Institute3
Karolinska Institutet3
National Heart, Lung, and Blood Institute (NHLBI)3
Kiadis Pharma2
National Cancer Institute (NCI)2
Northwell Health2
Peking University People's Hospital2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Graft vs Host Disease87
Myelodysplastic Syndromes14
Leukemia12
Hematologic Neoplasms10
Leukemia, Myeloid, Acute10
Bronchiolitis Obliterans Syndrome9
Precursor Cell Lymphoblastic Leukemia-Lymphoma7
Lymphoma6
Blast Crisis5
Hodgkin Disease5

Trials

Showing 51 to 75 of 87. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.